https://www.selleckchem.com/pr....oducts/Cisplatin.htm
Rituximab was the main cause of a seronegative response (39% seropositivity). There were no postvaccination symptomatic cases of COVID-19 among patients with AIIRD and one mild case in the control group. Major adverse events in patients with AIIRD included death (n=2) several weeks after the second vaccine dose, non-disseminated herpes zoster (n=6), uveitis (n=2), and pericarditis (n=1). Postvaccination disease activity remained stable in the majority of patients. mRNA BNTb262 vaccine was immunogenic in the majority of patients with A
Mi piace
Commento
Condividi
